Monheim, April 3, 2009 – Over the next two years, Bayer CropScience AG will be investing around EUR 30 million in the expansion of production capacities for the active ingredient prothioconazole at the Chemical Park in Dormagen. This investment comes in response to the growing demand in the fungicides business. Dormagen is one of the biggest Bayer CropScience production sites in the world.

Prothioconazole is approved in more than 40 countries for use in cereals, canola, soybeans, pulses and groundnuts. This modern crop protection substance is marketed globally and provides outstanding and long-lasting efficacy against a broad spectrum of plant diseases caused by fungal pathogens. Prothioconazole also counteracts the formation of mycotoxins, toxic substances produced by fungi which can harm human health and are a common cause of food poisoning. In the 2008 financial year, products based on prothioconazole were among Bayer CropScience’s ten most important products worldwide, with sales of EUR 246 million.

About Bayer CropScience

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience AG, a subsidiary of Bayer AG with annual sales of about EUR 6.4 billion (2008), is one of the world’s leading innovative cropscience companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of more than 18,000 and is represented in more than 120 countries. This and further news is available at: www.newsroom.bayercropscience.com.

More information is available at www.bayercropscience.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

back